Myocardial Infarction

Featuring: Prof Angela Maas

Antithrombotic Treatment After Coronary Intervention

New Perspectives On Atherogenic Dyslipidaemia And Cardiovascular Disease

Sodium–Glucose Cotransporter-2 Inhibitors

About

Myocardial infarction (MI) is one of the leading causes of death in the developed world. The annual prevalence of acute MI is nearly 3 million people worldwide, with more than 1 million deaths in the US.
Load more

Myocardial infarction (MI) is one of the leading causes of death in the developed world. The annual prevalence of acute MI is nearly 3 million people worldwide, with more than 1 million deaths in the US.

Acute MI can be divided into two categories, non-ST-segment elevation MI (NSTEMI) and ST-segment elevation MI (STEMI). Unstable angina is similar to NSTEMI, but cardiac markers are not elevated.
Load Less

Videos

Pages

Antithrombotic Treatment After Coronary Intervention: Agreement and Controversy

Tamara García Camarero, Jose M de la Torre Hernandez

European Cardiology Review 2020;15:e07.

DOI: https://doi.org/10.15420/ecr.2019.25.2
New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease

Alberto Lorenzatti, Peter P Toth

European Cardiology Review 2020;15:e04.

DOI: https://doi.org/10.15420/ecr.2019.06
Sodium–Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes

Muhammad Shahzeb Khan, Javed Butler

Cardiac Failure Review 2019;5(3):169–72.

DOI: https://doi.org/10.15420/cfr.2019.06.R1
Testosterone and the Heart

Michael G Kirby, Geoffrey Hackett, Sudarshan Ramachandran, et al

European Cardiology Review 2019;14(2):103–10

DOI: https://doi.org/10.15420/ecr.2019.13.1